ASCO: Abiraterone tolerated in high-risk prostate cancer

Share this article:
ASCO: Abiraterone Tolerated in High-Risk Prostate Cancer
ASCO: Abiraterone Tolerated in High-Risk Prostate Cancer

THURSDAY, May 17 (HealthDay News) -- For men with localized high-risk prostate cancer, neoadjuvant androgen deprivation therapy with abiraterone acetate (AA) plus leuprolide acetate (LHRHa) is well tolerated and has good pathological complete/near complete response (pCR/near pCR) rates, according to a study released May 16 in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Mary-Ellen Taplin, M.D., from Harvard Medical School and the Dana-Farber Cancer Institute in Boston, and colleagues conducted a randomized phase II trial for neoadjuvant AA/LHRHa in 58 men (median age, 58 years) with localized high-risk prostate cancer. Participants were randomly allocated to receive LHRHa (28 men) or AA/LHRHa/prednisone (30 men) for 12 weeks. After 12 weeks, all men received AA/LHRHa/prednisone for a further 12 weeks, followed by radical prostatectomy.

The researchers found that the pCR/near pCR was 25 percent overall, and was 34 percent for those treated with AA for 24 weeks and 15 percent for those treated with AA for 12 weeks. Grade 3 elevated aspartate aminotransferase/alanine aminotransferase and hypokalemia were seen in 9 and 5 percent of patients, respectively, and no grade 4 mineralocorticoid-related adverse events were observed.

"For this proportion of patients with high-risk disease to have very little to no detectable cancer in the prostate after six months of therapy is dramatic," Taplin said in a statement. "Our findings suggest that this combination therapy approach could improve outcomes for a substantial number of men, but larger, long-term trials are needed to confirm this approach."

Several authors disclosed financial ties to pharmaceutical companies, including Johnson & Johnson, which manufactures abiraterone acetate.

Abstract
More Information

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Women undergoing morcellation have in 27 in 10k uterine cancer prevalence

Women undergoing morcellation have in 27 in 10k ...

For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online.

Gene marker may help predict breast cancer response to tamoxifen

Gene marker may help predict breast cancer response ...

Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study.

Bike riding may up prostate cancer risk

Bike riding may up prostate cancer risk

Researchers found that cyclists who bike more may face a higher risk of prostate cancer, but not a greater chance of infertility or erectile dysfunction.